255 In the index

Sibutramine SIBU

A weight-loss drug (Meridia) that was FDA-approved before being pulled from the market in 2010, after a large human safety study showed it raised the risk of heart attack and stroke. It's a clear example of a drug that worked for short-term weight loss but wasn't safe long-term.

Also known as Meridia, Reductil

Effects Lose fat

Routes Oral

Legal status Unapproved / investigational

WADA Not listed

3D Molecular Structure of C₁₇H₂₆ClN

Drag to rotate · scroll to zoom

Chemistry

Formula: C17H26ClN
Molar mass: 279.8
CAS: 106650-56-0
PubChem CID: 5210

Reported dosing

Limited data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 10-15 mg/day (as approved before withdrawal)

Reported range 5-15 mg/day

Route Oral

Frequency Once daily

Duration Was intended for chronic use before market withdrawal

Was FDA-approved (Meridia) for weight loss but withdrawn from the US and global markets in 2010 after being linked to increased cardiovascular events; it has since been found as an undisclosed adulterant in some illegal 'natural' weight-loss products.

Where this comes from FDA prescribing information (withdrawn); post-marketing safety data; FDA adulterant-testing literature

Human data for this compound is limited. Read the figures above as a record of reported use rather than established dosing.